Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.

Li-Le Wang Lu Xu Shu-Hua Han Xiao-Li Zhu

Published in: Canadian respiratory journal (2024)

Our results confirmed that anlotinib inhibited DDP resistance in NSCLC cells, which might decrease MCL-1 expression via mediating the MET/STAT3/Akt pathway.

Keyphrases

cell proliferation
signaling pathway
poor prognosis
induced apoptosis
small cell lung cancer
tyrosine kinase
single cell
cell cycle arrest
binding protein
cell therapy
stem cells
oxidative stress
advanced non small cell lung cancer
endoplasmic reticulum stress
epidermal growth factor receptor
brain metastases